142 related articles for article (PubMed ID: 36163560)
61. Correlation exploration among CT imaging, pathology and genotype of pulmonary ground-glass opacity.
Cai Y; Chen T; Zhang S; Tan M; Wang J
J Cell Mol Med; 2023 Jul; 27(14):2021-2031. PubMed ID: 37340599
[TBL] [Abstract][Full Text] [Related]
62. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
[TBL] [Abstract][Full Text] [Related]
63. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
Chen ZY; Zhong WZ; Zhang XC; Su J; Yang XN; Chen ZH; Yang JJ; Zhou Q; Yan HH; An SJ; Chen HJ; Jiang BY; Mok TS; Wu YL
Oncologist; 2012; 17(7):978-85. PubMed ID: 22673630
[TBL] [Abstract][Full Text] [Related]
64. Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Jia Y; Ali SM; Saad S; Chan CA; Miller VA; Halmos B
Cancer Biol Ther; 2014 Aug; 15(8):970-4. PubMed ID: 24835218
[TBL] [Abstract][Full Text] [Related]
65. Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
Suda K; Ohara S; Fujino T; Hamada A; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
Clin Lung Cancer; 2022 Jan; 23(1):e60-e68. PubMed ID: 34750065
[TBL] [Abstract][Full Text] [Related]
66. Benign clear cell "sugar" tumor of the lung in a patient with Birt-Hogg-Dubé syndrome: a case report.
Gunji-Niitsu Y; Kumasaka T; Kitamura S; Hoshika Y; Hayashi T; Tokuda H; Morita R; Kobayashi E; Mitani K; Kikkawa M; Takahashi K; Seyama K
BMC Med Genet; 2016 Nov; 17(1):85. PubMed ID: 27871249
[TBL] [Abstract][Full Text] [Related]
67. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
[TBL] [Abstract][Full Text] [Related]
68. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
[TBL] [Abstract][Full Text] [Related]
69. Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules.
Park E; Ahn S; Kim H; Park SY; Lim J; Kwon HJ; Han YB; Lee CT; Cho S; Chung JH
J Thorac Oncol; 2018 Nov; 13(11):1776-1783. PubMed ID: 30121391
[TBL] [Abstract][Full Text] [Related]
70. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.
Pelosi G; Pellegrinelli A; Fabbri A; Tamborini E; Perrone F; Settanni G; Busico A; Picciani B; Testi MA; Militti L; Maisonneuve P; Valeri B; Sonzogni A; Proto C; Garassino M; De Braud F; Pastorino U
Virchows Arch; 2016 Jun; 468(6):651-62. PubMed ID: 27056568
[TBL] [Abstract][Full Text] [Related]
71. The nuclear accumulation of the Fanconi anemia protein FANCE depends on FANCC.
Léveillé F; Ferrer M; Medhurst AL; Laghmani el H; Rooimans MA; Bier P; Steltenpool J; Titus TA; Postlethwait JH; Hoatlin ME; Joenje H; de Winter JP
DNA Repair (Amst); 2006 May; 5(5):556-65. PubMed ID: 16513431
[TBL] [Abstract][Full Text] [Related]
72. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
Tønnesen E; Lade-Keller J; Stougaard M
Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
[TBL] [Abstract][Full Text] [Related]
73. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.
Gordon SM; Alon N; Buchwald M
J Biol Chem; 2005 Oct; 280(43):36118-25. PubMed ID: 16127171
[TBL] [Abstract][Full Text] [Related]
74. Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.
Lv J; Zhang H; Ma J; Ma Y; Gao G; Song Z; Yang Y
Clin Radiol; 2018 Jun; 73(6):590.e1-590.e8. PubMed ID: 29454587
[TBL] [Abstract][Full Text] [Related]
75. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
76. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
77. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
78. [Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma].
Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
[TBL] [Abstract][Full Text] [Related]
79. Segmentectomy of the left superior segment (S
Shimizu K; Nakazawa S; Mogi A; Kuwano H
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1302-1304. PubMed ID: 28986040
[No Abstract] [Full Text] [Related]
80. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
